KRIBIOLISA™ Catumaxomab ELISA (REMOVAB™)
ELISA for the detection of Catumaxomab in human serum and plasma. Lead time for this kit is 5 weeks. About the kit: - Uses anti-idiotypic monoclonal antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Validated as per US FDA guidelines for Bioassays - Developed using the innovator drug as calibrator - Shelf life: 1 year
Receive your quote directly from the manufacturer.
Catumaxomab (Removab(), is a trifunctional IgG2 antibody approved for the treatment of malignant ascites (in 2009), a condition found in patients with a variety of epithelial cancers. It is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD3 receptors. It also has an intact immunoglobulin gamma constant region allowing it to bind to Fc_ I, IIa, and III receptors. By binding to CD3 on T cells, EpCAM on cancer cells, and Fc_ receptors on accessory immune cells like macrophages and NK cells, Catumaxomab brings immune cells into close proximity to EpCAM positive cancer cells. As a functional antibody, Catumaxomab also stimulates bound NK cells to release cytotoxic mediators like granzyme or bound macrophages to phagocytose the cancer cell.
